{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T23:54:17Z","timestamp":1790553257247,"version":"4.1.0"},"reference-count":11,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2020,10,9]],"date-time":"2020-10-09T00:00:00Z","timestamp":1602201600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2021,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objectives<\/jats:title><jats:p>SIMPLICITY (NCT01244750) is an observational study of patients with chronic\u2010phase chronic myeloid leukemia (CP\u2010CML) in routine clinical practice receiving first\u2010line tyrosine kinase inhibitors (TKIs). We evaluated TKI treatment changes and how switching affects clinical response in patients recruited in Europe with \u22653\u00a0years of follow\u2010up.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The SIMPLICITY European cohort (France, Germany, Italy, the Netherlands, Russia, and Spain) included 431 patients. 370 (86%) were followed for \u22653\u00a0years.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Proportions of patients experiencing treatment interruptions, TKI switching, and discontinuations decreased over 3\u00a0years\u2019 follow\u2010up. Intolerance was a key driver for treatment changes. Complete cytogenetic response (CCyR) was achieved in 87.5% of patients switching TKI within 3\u00a0years of initiation vs 91.7% of non\u2010switchers. Major molecular response (MMR) was achieved in 82.4% of switchers vs 92.9% of non\u2010switchers. Over 3\u00a0years, not switching TKI was a strong predictor for achieving CCyR or MMR (both <jats:italic>P<\/jats:italic>\u00a0&lt;\u00a0.05). Three\u2010year survival remained high, irrespective of treatment changes (95.3% switchers, 96.4% non\u2010switchers).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>European patients with CP\u2010CML who do not switch TKI are more likely to achieve clinical response, while intolerance is a key driver for switching. Successful CML management may require careful selection of initial TKI, with early monitoring of response and intolerance.<\/jats:p><\/jats:sec>","DOI":"10.1111\/ejh.13524","type":"journal-article","created":{"date-parts":[[2020,9,29]],"date-time":"2020-09-29T02:11:39Z","timestamp":1601345499000},"page":"82-89","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Treatment patterns and clinical outcomes of tyrosine kinase inhibitors in chronic\u2010phase CML in clinical practice: 3\u2010year European SIMPLICITY data"],"prefix":"10.1111","volume":"106","author":[{"given":"Carlo","family":"Gambacorti\u2010Passerini","sequence":"first","affiliation":[{"name":"University of Milano Bicocca San Gerardo Hospital  Monza Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Chen","sequence":"additional","affiliation":[{"name":"Bristol\u2010Myers Squibb  Princeton NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Davis","sequence":"additional","affiliation":[{"name":"Bristol\u2010Myers Squibb  Princeton NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ginny P.","family":"Sen","sequence":"additional","affiliation":[{"name":"ICON plc  San Francisco CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christy","family":"Guyan","sequence":"additional","affiliation":[{"name":"ICON plc  San Francisco CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R\u00fcdiger","family":"Hehlmann","sequence":"additional","affiliation":[{"name":"European LeukemiaNet (ELN)  Weinheim Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauricette","family":"Michallet","sequence":"additional","affiliation":[{"name":"Centre Hospitalier Lyon\u2010Sud  Pierre\u2010B\u00e9nite France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald","family":"Paquette","sequence":"additional","affiliation":[{"name":"Cedars\u2010Sinai Medical Center  Los Angeles CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart L.","family":"Goldberg","sequence":"additional","affiliation":[{"name":"John Theurer Cancer Center Hackensack University Medical Center  Hackensack NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,10,9]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-05-282632"},{"key":"e_1_2_9_3_1","unstructured":"National Comprehensive Cancer Network (NCCN).NCCN Guidelines Chronic Myelogenous Leukemia Version 1.2019;2018.https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/cml.pdf. Accessed April 22 2020."},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0776-2"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2016.139"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.104"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24887"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25306"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2012.30"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.246"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2014.10.019"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1177\/2040620714560305"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.13524","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ejh.13524","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.13524","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,4]],"date-time":"2023-09-04T10:33:21Z","timestamp":1693823601000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ejh.13524"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,9]]},"references-count":11,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["10.1111\/ejh.13524"],"URL":"https:\/\/doi.org\/10.1111\/ejh.13524","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,9]]},"assertion":[{"value":"2020-07-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-09-22","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-10-09","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}